Background: Urine biomarkers have helped identify persons at risk for progressing to kidney disease in the setting of HIV infection. We explored factors associated with changes in 3 urine biomarkers over 10 years among women living with HIV.
INTRODUCTION
HIV infection is associated with increased risk of developing chronic kidney disease (CKD), 1 and among persons with HIV infection, the development of CKD is associated with increased morbidity and mortality. [1] [2] [3] Urine biomarkers have previously been shown to capture subclinical kidney injury that is not detectable by standard clinical measures such as serum creatinine-based estimated glomerular filtration rate (eGFR) or urine protein concentrations. [4] [5] [6] [7] [8] [9] [10] In addition, several urine biomarkers have shown the ability to distinguish the contributions of specific risk factors for subclinical kidney disease. This attribute is particularly important in HIV-infected persons because CKD can arise as a consequence of multiple different etiologies including chronic antiretroviral therapy (ART), HIV infection itself, hepatitis C virus (HCV) coinfection, and comorbid chronic illnesses such as diabetes mellitus and hypertension. 1, 2, [11] [12] [13] [14] [15] [16] [17] Furthermore, the presence of 2 abnormal alleles for the APOL1 gene predisposes a subset of African Americans to more extensive glomerular injury and faster CKD progression. [18] [19] [20] [21] Several distinct urine biomarkers have been evaluated that are predictive of progressive kidney decline and incident CKD. Our previous work in the Women's Interagency HIV Study (WIHS) identified biomarkers that reflect different pathophysiologic aspects of kidney injury, which could aid in early detection. 4, 6, [22] [23] [24] [25] The strongest associations with declines in kidney function have been observed with the urine albumin-to-creatinine ratio (ACR), alpha-1-microglobulin (a1m), and interleukin-18 (IL-18) concentrations. 4, 22, 23, 25 Elevations of the ACR have been associated with declining kidney function in a variety of diseases, including HIV, and are indicative of glomerular injury of the kidney. 4, 25 The a1m is a low-molecular-weight protein that reflects proximal tubular dysfunction when elevated in urine samples. 4, 22 IL-18 is a proinflammatory cytokine involved in cell-mediated immunity, and its urine levels correspond to the extent of proximal tubular injury. 4, 25 In multivariable analyses with comprehensive covariate adjustment, each of these 3 markers has been independently associated with faster decline in kidney function and higher mortality risk. 4, [22] [23] [24] A major step in understanding the clinical utility of a kidney biomarker involves establishing whether or not serial measures capture longitudinal changes in kidney health. Biomarkers are of lesser value if they cannot capture dynamic changes in risk over time. Therefore, biomarker research in HIV-infected persons needs to evaluate the long-term changes in novel urine biomarkers and to understand whether they are responsive to changes in important health status measures, including immune function. In this study, to improve on previous studies that have used biomarker measures from a single time, we present data investigating 10-year changes of 3 urine biomarkers among women living with HIV. Our primary hypothesis was that improvements in systemic immune status over 10 years would lead to favorable changes in the urine biomarker profile of kidney injury.
SUBJECTS AND METHODS

Study Design and Population
The WIHS is a large, multicenter, prospective cohort study of HIV-infected women and at-risk HIV-uninfected women in the United States, 26 ongoing since 1993. The WIHS has been described elsewhere. 26, 27 At semiannual visits, participants are interviewed and examined, and serum specimens are collected and stored in a 280°C freezer. During the time of this study, women were enrolled in 6 U.S. sites (Bronx, Brooklyn, Chicago, Los Angeles, San Francisco, and Washington, DC). The enrolled women are representative of U.S. women living with HIV in terms of demographic and clinical parameters. 26 The specific substudy of this analysis, known as the WIHS HIV Kidney Aging study, is a nested cohort study designed to evaluate incident kidney disease in the setting of HIV infection. 4, 22, 28, 29 Baseline measures of urine biomarkers were conducted on stored urine samples that were collected between October 1999 and March 2000 (year 0). Follow-up measures were made in a subsequent collection in 2010 (year 10). Among 908 women with baseline measures of urine ACR, IL-18, and a1m, we selected a random sample among those women with available stored urine at year 10 to include in this study (N = 294). WIHS was approved by institutional review boards at all study sites. This study of kidney injury was also approved by the University of California, San Francisco, San Francisco Veterans Affairs Medical Center, Johns Hopkins University, and Yale University committees on human research. All WIHS participants provided written and informed consent. The procedures were consistent with the Helsinki Declaration.
including baseline, peak, nadir, and time-averaged values. Candidate variables that were considered as potential predictors of biomarker changes included the following: timeaveraged HIV viral load (in copies per milliliter), peak HIV viral load (in copies per milliliter), most recent HIV viral load (copies per milliliter), time-averaged CD4 cell count (cells per microliter), nadir CD4 cell count during study period (cells per microliter), nadir CD4 cell count before year 0 (cells per microliter), most recent CD4 cell count (cells per microliter), diastolic blood pressure (DBP) (in mm Hg), systolic blood pressure (in mm Hg), history of diabetes mellitus (yes or no, by laboratory confirmation or self-report), history of hypertension (yes or no, by self-report or confirmed on examination or use of antihypertensive medication), HCV coinfection (yes or no, by the presence of HCV antibody or RNA), current smoking status (yes or no), smoking history (yes or no), body mass index (BMI) (in kg/m 2 ), waist circumference (in centimeters), age (in years), serum low density lipoprotein cholesterol (in mg/dL), serum triglyceride (in mg/dL), serum high density lipoprotein (HDL) cholesterol (in mg/dL), history of AIDS (yes or no), and race (African American, white, or other). Viral suppression was defined as ,80 copies per milliliter. We also considered changes from baseline for each continuous variable as candidate predictors.
Outcome
The primary outcome was the change in 3 separate urine biomarkers, ACR, a1m, and IL-18, which were measured at year 0 and at year 10 of this study. All urinary kidney injury biomarkers were measured at the Cincinnati Children's Hospital Medical Center Biomarker Laboratory. Urine albumin was measured by immunoturbidimetry using a Siemens Dimension Xpand plus HM clinical analyzer (Siemens, Munich, Germany). Urine a1m was measured by a commercially available assay (Siemens BN II Nephelometer; Siemens). Urine IL-18 was measured using a commercially available enzyme-linked immunosorbent assay kit (Medical & Biological Laboratories Co, Nagoya, Japan). All urine specimens were in continuous storage without previous freeze-thaw. Laboratory personnel were blinded to clinical information about the participants and specimens were evaluated in random order. Assays were performed in 2010 for baseline samples and in 2015 for year 10 samples. We repeated 50 baseline measurements on specimens in 2015 and found no evidence for assay drift or bias in any of the assays. For this repeat testing, the Kendall coefficients of concordance W test statistic (and P-value) were as follows: 0.94 (P , 0.001) for IL-18, 0.94 (P , 0.001) for urine albumin, 1.0 (P , 0.001) for urine creatinine, and 0.96 (P , 0.001) for a1m. The intraassay coefficients of variation for the urine measures were: albumin, 5.9%; a1m, 5.2%; and IL-18, 5.2%.
Statistical Analysis
Demographic and clinical characteristics were summarized descriptively at each study visit (year 0 and year 10). We used quantile regression to examine the patterns and distributions of change in each urine biomarker over 10 years of follow-up. This method enables comparison of biomarker concentrations at the median, quartiles, and other percentiles from baseline to year 10 and is particularly helpful in exploring differences in the tails of distributions.
We identified patterns of changes in biomarker levels using k-means clustering to partition subjects into distinct groups. Our cluster construction was informed solely by the baseline and year 10 levels of each biomarker. We used the SAS FASTCLUS procedure to identify outliers and reduce their effect on cluster centers, using the strict option and cubic clustering criterion to determine the final number of clusters. For each biomarker, clusters were compared over the 10-year study period by plotting percentiles to compare relative differences within and between clusters. We used multinomial logistic regression to identify factors associated with cluster membership, using cluster 1 as the reference group. Finally, multivariable analysis of variance was used to model predictors and patterns of change in all 3 biomarkers simultaneously. We standardized each biomarker (to a mean of zero and variance regression model uses the correlations among the errors in different equations to improve efficiency of the regression estimates while enabling potentially different predictors for each dependent variable. Because many of the candidate covariates were intercorrelated, we used the least absolute shrinkage and selection operator (LASSO) method for variable selection 31 (R package glmnet). We then applied Bayesian Model Averaging (BMA) to the LASSO-selected predictors, retaining variables with a posterior probability of greater than 35%. We used the mlogitBMA package for R 32 to perform BMA for multinomial logit models. All other analyses were conducted using SAS (version 9.4, Cary, NC).
RESULTS
Demographic and clinical characteristics of the 294 women at baseline (year 0) and follow-up (year 10) are summarized in Table 1 . Of note, over 10 years, the proportion of women diagnosed with hypertension nearly doubled, with an increase in the prevalence of antihypertensive use during this time. The prevalence of diabetes mellitus and HCV coinfection remained stable, and all serum cholesterol parameters (low density lipoprotein, HDL, and triglycerides) were on average, improved after 10 years. Use of ART increased over 10 years, with correspondingly large increases in CD4 cell count and the proportion of women with viral suppression. There was very little change in eGFR by creatinine over 10 years (97-95 mL/min/1.73 m 2 ). Figure 1 shows distributions of urine biomarker levels at baseline and year 10. Median IL-18 concentration declined by nearly 50% over 10 years; in contrast, median a1m concentration rose by approximately 50%. Although median ACR levels were similar at baseline and year 10, the distribution of values (10th, 90th percentiles) was somewhat wider at year 10 (2-92 mg/g) compared with baseline (4-43 mg/g). The cluster analysis identified four distinct patterns of biomarker change (Fig. 2) . Cluster 1 appeared to be the healthiest subset with the lowest levels of IL-18 and a1m throughout the follow-up period. In contrast, cluster 2 had the highest levels of both IL-18 and a1m. Cluster 3 was distinguished by having the highest urinary ACR levels at both time points and a1m levels that rose during follow-up. Cluster 4 was notable for high baseline IL-18 levels that declined sharply during follow-up.
Next, we performed multivariable regression analysis to identify predictors of biomarker changes. Figure 3 depicts the relative importance of each candidate variable, which represents the posterior probability that each variable has a nonzero association with each biomarker outcome. Dominant factors for IL-18 changes included higher year 10 HIV viral load, higher baseline BMI, higher change in waist circumference, lower year 10 CD4 cell count, and higher year 10 HDL cholesterol. The primary determinants of increases in a1m levels were the nadir CD4 cell count both before baseline and during the follow-up period. The most important determinant of increasing ACR values was the year 10 DBP.
Using variables selected by the LASSO and BMA procedures, we performed a multivariable-adjusted multivariable analysis of variance regression analysis of changes from baseline to year 10 in all 3 biomarker levels (parsimonious model shown in Table 2 , full model available in Table 1 , Supplemental Digital Content, http://links.lww.com/QAI/ A935). The selected predictors showed distinct associations with changes in each biomarker. Factors associated with increases in IL-18 were higher BMI at baseline, increasing waist circumference, lower HDL cholesterol at year 10, HCV coinfection, lower CD4 cell count, and higher HIV viral load, both at year 10. Factors associated with increases in a1m included decreasing BMI over the study period, smoking tobacco at baseline, higher DBP at baseline, HCV coinfection, higher nadir CD4 cell count before baseline and decreasing nadir CD4 between year 0 and year 10. Finally, factors associated with increases in ACR included higher triglycerides at year 10, higher DBP at year 10, HCV infection, and higher HIV viral load at year 10. In sensitivity analyses, the findings were similar after indexing to urine creatinine. For a1m, the rise over 10 years appeared to be modestly stronger when evaluated using measures indexed for creatinine (see Figure 1 and Table 3 , Supplemental Digital Content, http://links.lww.com/QAI/A935).
We then used multinomial logistic regression analyses to identify factors that were independently associated with each of the clusters depicted in Figure 2 (with model shown in Table 2 , Supplemental Digital Content, http://links.lww.com/ QAI/A935), using the healthiest cluster (cluster 1) as the reference group. Characteristics significantly associated with greater odds of cluster 2 membership were current smoking (odds ratio [OR] = 4.55, P , 0.001) and a history of AIDS (OR = 2.71, P = 0.006), whereas higher time-averaged CD4 cell count was associated with a lower odds of cluster 2 membership (OR = 0.51 per doubling of CD4, P = 0.006). Current smoking was the only independent predictor of cluster 3 membership (OR = 2.23, P = 0.03), whereas other factors showed little association. Compared with cluster 1, higher time-averaged CD4 cell count was associated with lower likelihood of being in cluster 4 (OR = 0.56 per doubling of CD4, P = 0.01) compared with cluster 1.
DISCUSSION
In this prospective cohort of women living with HIV, we found that the urine IL-18 concentration is a dynamic biomarker that decreased over 10 years of follow-up and appeared to be strongly influenced by changes in viral load and CD4 cell count in cluster analysis. In contrast, a1m levels rose over time, whereas ACR showed little change on average over the course of 10 years of follow-up. This is a novel finding in that each of these biomarkers demonstrated a distinct trajectory in these HIV-infected women over the same period. Although IL-18 levels declined substantially over 10 years, particularly in those women with controlled viremia, this beneficial effect was mitigated by higher baseline BMI, increases in waist circumference, lower HDL cholesterol, higher year 10 viral load, lower year 10 CD4 cell count, and HCV coinfection. Levels of a1m increased on average over 10 years, and similarly, appeared to be influenced by HCV coinfection, and also higher baseline DBP, smoking, and lower nadir CD4 cell count at both baseline and during the study period. Lower BMI at followup was also associated with increasing a1m, but the change in median BMI from year 0-10 was from 27 to 28 kg/m 2 . Finally, although ACR levels were stable on average and remained low in most patients, they were more likely to increase over time in those with higher triglycerides, higher DBP, higher HIV viral load, and in those with HCV coinfection.
The decline in IL-18 paralleled improvements in viral control, and the mechanisms by which this occurs are not established. Because urine IL-18 concentrations have been found to be associated with both the incidence of CKD and mortality in the setting of HIV infection, they have been hypothesized to reflect both ongoing subclinical kidney injury and potentially to be a marker of systemic inflammation. It is noteworthy that IL-18 concentrations decreased substantially during the follow-up period, whereas limited changes were seen with ACR and eGFR. 25 Because HIV replication is known to occur in renal tubular cells, 8 the findings of this study may support the proposed mechanism whereby HIV treatment leads to reductions in viral replication and lower local inflammation within the kidney.
The increases in a1m at 10 years of follow-up were an unexpected finding. Because CD4 cell counts and viral suppression dramatically improved over the 10-year study period, a pattern for a1m similar to IL-18 might have been expected. The divergent findings for IL-18 and a1m warrant additional investigation. In future studies, we plan to measure additional time points for the biomarkers to evaluate changes related to ART agents, such as tenofovir. ACR is a strong prognostic marker for morbidity and mortality in WIHS, 25, [33] [34] [35] [36] [37] [38] yet in this study, it remained relatively stable over 10 years, despite significant improvements in control of HIV infection. Kidney function, as measured by eGFR, remained relatively constant over this period as well, allowing us to explore those factors that affect markers of tubular and glomerular function and injury independent of established clinical measures of kidney disease. Over the same period, there was a significant increase in diagnosis and treatment of hypertension, and of note, we found that higher DBP was associated with increases in ACR. However, the lack of change in ACR over the decade of follow-up may reflect that HIV disease has a greater impact on tubular injury than on glomerular injury in this contemporary cohort of HIV-infected women. Previous research in WIHS has shown that all 3 biomarkers are strongly predictive of kidney function decline longitudinally, so their prognostic relevance has been established. All changes in biomarkers in this study should be considered in the setting of relative improvements in HIV control. As patients were increasingly treated for HIV during this decade of observation, residual inflammation may have persisted because of ART-related toxicities or complications, and improved survival may have led to longer periods of atrisk time to develop chronic diseases that are proinflammatory. In contrast to previous work, where IL-18 was primarily driven by viral status, 28 here we see an effect of metabolic disease on inflammation. These markers have been helpful in identifying evidence for kidney disease, 4, 6, [22] [23] [24] [25] and this work provides further evidence that the biomarkers could be valuable tools to monitor preclinical kidney disease status. In the evolution of a biomarker toward clinical practice, it must be shown to be not only prognostic, but also to be responsive to changes in health status.
There are some limitations to the interpretation of these data. We only measured 3 biomarkers out of many potential measures that could be indicative of kidney disease onset or progression. These biomarkers were chosen because they were associated with CKD and mortality in previous WIHS studies. This study only included women and therefore may not be readily generalizable to men. The first urine samples were collected over a decade before measurement; some degradation may lead to a nondifferential error in quantification of urine biomarkers, but this is unlikely given the concordance noted on repeat testing from a sample of 50 specimens. Importantly, there is a possibility of residual confounding not accounted for in the modeling and a survival bias in the cohort and therefore the study sample. We did not focus on the relative impact of tenofovir exposure in this study, because of the limited exposure to tenofovir in this subset of participants at the time of biomarker measurement. Additionally, most participants in this cohort did not initiate treatment with tenofovir disoproxil fumarate until [2005] [2006] [2007] [2008] . To more concretely understand the association of tenofovir exposure with these urine biomarkers of kidney injury, we plan to conduct measures of the biomarkers after additional years of followup to allow longer cumulative durations of tenofovir use.
There are several important strengths to this study. To our knowledge, this is the largest study to date of urine biomarker changes in HIV-infected women. Moreover, we had a long duration of follow-up from an ethnically and clinically diverse cohort. This is particularly important in the setting of understanding disease progression among different genetic susceptibilities for CKD. In addition, we were able to consider a large number of possible predictors in helping to understand what factors contributed most to changes in biomarker levels over time, including status of HIV control and comorbidities.
In summary, we present data supporting that IL-18 is a dynamic urine biomarker that changes in tandem with control of HIV disease and that a1m may be a biomarker that reflects inflammation from a number of pathophysiological mechanisms. In contrast, ACR was relatively static over 10 years in this longitudinal cohort. Although further study is required to understand the effects of antiretroviral associated nephrotoxicity on changes in urine biomarkers, this work opens the door for additional research to understand patterns of biomarker change that may predict incidence and progression of CKD.
